Adrenal cortical carcinoma (ACC)

Active Ingredient: Mitotane

Indication for Mitotane

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma (ACC).

The effect of mitotane on non functional adrenal cortical carcinoma is not established.

For this indication, competent medicine agencies globally authorize below treatments:

1.5-4 g/m² in 2-3 divided doses daily

Route of admnistration

Oral

Defined daily dose

1.5 - 4 g per m² of body surface area (BSA)

Dosage regimen

From 0.5 To 1.333 g per m² of body surface area (BSA) 3 time(s) per day every day

Loading dose

1.5 g per m² of body surface area (BSA)

Detailed description

The experience in children is limited.

The paediatric posology of mitotane has not been well characterised but appears equivalent to that of adults after correction for body surface.

Treatment should be initiated at 1.5 to 3.5 g/m²/day in children and adolescents with the objective of reaching 4 g/m²/day. Mitotane plasma levels should be monitored as for adults, with particular attention when plasma levels reach 10 mg/L as a quick increase in plasma levels may be observed. Dose may be reduced after 2 or 3 months according to the mitotane plasma levels or in case of serious toxicity.

Dosage considerations

Mitotane should be taken with a glass of water during meals containing fat-rich food.

Active ingredient

Mitotane
Mitotane is an adrenal cytotoxic active substance, although it can apparently also cause adrenal inhibition without cellular destruction. Available data suggest that mitotane modifies the peripheral metabolism of steroids and that it also directly suppresses the adrenal cortex. The administration of mitotane alters the extra-adrenal metabolism of cortisol in humans, leading to a reduction in measurable 17-hydroxy corticosteroids, even though plasma levels of corticosteroids do not fall. Read more about Mitotane

Related medicines

Summary of Product Characteristics (SPC) 2020: LYSODREN Tablet

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.